arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström's Macroglobulinemia V :
November 03, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
...
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110
October 15, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Based on evidence of activity, T-cell lymphomas...
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive solid tumors into its Phase 1b expansion trial with ARGX-110
September 18, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
18 September 2014 Breda, the Netherlands /...
arGEN-X' core patents protecting lead clinical candidates ARGX-110 and ARGX-111 receive accelerated grant in the United States
September 17, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
17 September 2014 Breda, the Netherlands /...
arGEN-X appoints Petercam NV as Liquidity Provider to facilitate trading on Euronext Brussels
September 15, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
15 September 2014 Breda, the Netherlands / Ghent,...
arGEN-X - Business Update and First Half 2014 Results
August 27, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
27 August 2014 Breda, the Netherlands /...
arGEN-X: Notice of Results for the First Half 2014 and Business Update
August 20, 2014 11:58 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
NOT FOR RELEASE, PUBLICATION OR...
arGEN-X announces positive preclinical results for ARGX-113
August 19, 2014 07:53 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,...
arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period in relation to its Initial Public Offering
August 11, 2014 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
NOT FOR RELEASE, PUBLICATION OR...
arGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference
August 05, 2014 11:45 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,...